Ashley Gallagher is an assistant editor at Pharmacy Times®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.
Study: Some Health Care Professionals Found to Spread COVID-19 Misinformation Via Social Media
August 25th 2023Investigators determined that there needs to be an evaluation of harm caused by pharmacy professionals who are in unique positions on social media, propagating misinformation about COVID-19, vaccines, treatment, masks, and other conspiracy theories.
Read More
Study: Multilevel Data Model Helps Estimate Likelihood of Delays in Cancer Treatment
August 24th 2023In the study, investigators incorporated data from electronic health records and social determinants of health into the model to determine the likelihood in delays when starting cancer therapy.
Read More
FDA Approves Hepzato Kit for Liver-Directed Treatment of Metastatic Uveal Melanoma
August 16th 2023Melphalan/hepatic delivery system (Hepzato Kit; Delcath Systems Inc) is currently the only liver-directed therapy approved by the FDA for the treatment of netastatic uveal melanoma and percutaneous hepatic perfusion.
Read More
Approximately 57% of individuals who were shown a flowchart of the FDA vaccine approval process were very or somewhat likely to recommend a respiratory syncytial virus vaccine to a pregnant family member or friend compared to only 40% of those who were not shown the process.
Read More
mRNA-1273 Vaccine Associated With Lower Risk of Adverse Events, Likelihood of COVID-19 Diagnosis
August 4th 2023Compared to the BNT162b2 vaccine, the mRNA-1273 vaccine was associated with a lower risk of adverse events, which investigators speculate was due to interrelated safety and efficacy.
Read More
IVIG-Based Treatment Increased Survival Rates of Renal Transplantation, Stabilizing Graft Function
August 2nd 2023With an intravenous immunoglobulin-based treatment protocol, individuals who underwent renal transplantation and who were presensitized achieved intermediate-term graft and recipient survival results at 98%.
Read More